Tags

Type your tag names separated by a space and hit enter

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Acta Diabetol. 2007 Dec; 44(4):187-92.AD

Abstract

The aim of this study was to compare the efficacy of treatment with insulin alone, insulin plus acarbose, insulin plus metformin, or insulin plus rosiglitazone in type 2 diabetic subjects who were previously on insulin monotherapy, and to evaluate the effects of these treatments on cardiovascular risk factors including lipid profile, C-reactive protein (CRP) and fibrinogen. Sixty-six poorly controlled type 2 diabetic patients on insulin monotherapy were involved. They were randomized to insulin alone, insulin plus acarbose, insulin plus metformin, or insulin plus rosiglitazone groups for 6 months period. Mean fasting and postprandial glucose values as well as HbA1c levels significantly decreased in all groups. The greatest improvement in HbA1c was observed in insulin plus rosiglitazone (2.4%) and in insulin plus metformin (2%) groups. Daily total insulin dose was increased to 12.7 units/day in insulin alone group, decreased to 4.7 units/day in insulin plus rosiglitazone group, to 4.2 units/day in insulin plus metformin group, and to 2.7 units/day in insulin plus acarbose group. Least weight gain occurred in insulin plus metformin group (1.4 kg) and greatest weight gain occurred in insulin plus rosiglitazone group (4.6 kg). No significant change in lipid levels--except serum triglycerides--was observed in any groups. CRP and fibrinogen levels decreased in all groups, but the decrease in fibrinogen level was significantly greater in insulin plus rosiglitazone group. All groups were comparable in hypoglycemic episodes. No serious adverse event was noted in any group.

Authors+Show Affiliations

Department of Endocrinology and Metabolic Diseases, Baskent University Faculty of Medicine, 5. sokak No: 48, 06490 Bahcelievler/Ankara, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17726570

Citation

Yilmaz, Hamiyet, et al. "Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Rosiglitazone or Insulin and Acarbose in Type 2 Diabetes." Acta Diabetologica, vol. 44, no. 4, 2007, pp. 187-92.
Yilmaz H, Gursoy A, Sahin M, et al. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol. 2007;44(4):187-92.
Yilmaz, H., Gursoy, A., Sahin, M., & Guvener Demirag, N. (2007). Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetologica, 44(4), 187-92.
Yilmaz H, et al. Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Rosiglitazone or Insulin and Acarbose in Type 2 Diabetes. Acta Diabetol. 2007;44(4):187-92. PubMed PMID: 17726570.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. AU - Yilmaz,Hamiyet, AU - Gursoy,Alptekin, AU - Sahin,Mustafa, AU - Guvener Demirag,Nilgun, Y1 - 2007/08/29/ PY - 2006/10/23/received PY - 2007/07/05/accepted PY - 2007/8/30/pubmed PY - 2008/3/13/medline PY - 2007/8/30/entrez SP - 187 EP - 92 JF - Acta diabetologica JO - Acta Diabetol VL - 44 IS - 4 N2 - The aim of this study was to compare the efficacy of treatment with insulin alone, insulin plus acarbose, insulin plus metformin, or insulin plus rosiglitazone in type 2 diabetic subjects who were previously on insulin monotherapy, and to evaluate the effects of these treatments on cardiovascular risk factors including lipid profile, C-reactive protein (CRP) and fibrinogen. Sixty-six poorly controlled type 2 diabetic patients on insulin monotherapy were involved. They were randomized to insulin alone, insulin plus acarbose, insulin plus metformin, or insulin plus rosiglitazone groups for 6 months period. Mean fasting and postprandial glucose values as well as HbA1c levels significantly decreased in all groups. The greatest improvement in HbA1c was observed in insulin plus rosiglitazone (2.4%) and in insulin plus metformin (2%) groups. Daily total insulin dose was increased to 12.7 units/day in insulin alone group, decreased to 4.7 units/day in insulin plus rosiglitazone group, to 4.2 units/day in insulin plus metformin group, and to 2.7 units/day in insulin plus acarbose group. Least weight gain occurred in insulin plus metformin group (1.4 kg) and greatest weight gain occurred in insulin plus rosiglitazone group (4.6 kg). No significant change in lipid levels--except serum triglycerides--was observed in any groups. CRP and fibrinogen levels decreased in all groups, but the decrease in fibrinogen level was significantly greater in insulin plus rosiglitazone group. All groups were comparable in hypoglycemic episodes. No serious adverse event was noted in any group. SN - 0940-5429 UR - https://www.unboundmedicine.com/medline/citation/17726570/Comparison_of_insulin_monotherapy_and_combination_therapy_with_insulin_and_metformin_or_insulin_and_rosiglitazone_or_insulin_and_acarbose_in_type_2_diabetes_ DB - PRIME DP - Unbound Medicine ER -